摘 要：
目的：系统探讨神曲消食口服液联合布拉氏酵母菌散治疗轮状病毒性肠炎患儿的临床疗效及肠道菌群变化的影响，为疾病评估及个体化治疗提供循证依据。方法：选取2021年1月-2025年1月于我院就诊的74例轮状病毒性肠炎患儿为研究对象，每组37人，每组均给予常规治疗，对照组在常规治疗基础上加用布拉氏酵母菌散，观察组在对照组基础上加用神曲消食口服液。分析74例患儿临床资料，比较两组患儿的中医证候量化评分、临床疗效及大便球杆比。结果：观察组和对照组治疗前后白细胞、淋巴细胞绝对值、超敏C反应蛋白差异无统计学意义（P＞0.05）；治疗后超敏C反应蛋白较治疗前好转（P<0.05）。治疗前，两组中医症状评分差异无统计学意义。治疗后，观察组及对照组中医症状评分（腹泻、食欲不振、呕吐、腹痛）均有好转（P<0.05），且观察组明显优于对照组（P<0.05）。观察组临床疗效（总有效率93.2%）优于对照组（总有效率89.2%），临床疗效显著（P<0.05）。治疗前两组粪便球杆比差异无统计学意义，治疗后两组球杆比值均较前好转（P<0.05），且观察组治疗后球杆比值（0.227±0.084）较治疗前（0.495±0.244）显著改善（P<0.05），提示观察组干预方案疗效确切，可显著改善患者临床症状及相关指标。结论：神曲消食口服液联合布拉氏酵母菌散能显著改善轮状病毒性肠炎患儿的临床症状缓解，更能辅助调节肠道菌群的失衡。
关键词：轮状病毒性肠炎；腹泻；神曲消食口服液；布拉氏酵母菌散；疗效
Abstract:
Objective: To systematically evaluate the clinical efficacy of Shenqu Xiaoshi Oral Liquid combined with Saccharomyces boulardii powder in treating children with rotavirus gastroenteritis, and to analyze its impact on intestinal microbiota, thereby providing evidence-based support for disease assessment and individualized treatment. Methods: A total of 74 children diagnosed with rotavirus gastroenteritis were enrolled from our hospital between January 2021 and January 2025. They were randomly divided into two groups (n=37 each). Both groups received standard therapy; the control group additionally received Saccharomyces boulardii powder, while the observation group received the same plus Shenqu Xiaoshi Oral Liquid. Clinical data from all 74 patients were analyzed, including TCM syndrome scoring, clinical outcomes, and stool form-to-stick ratio. Results: No significant differences were observed between the two groups regarding white blood cell count, absolute lymphocyte count, or hypersensitive C-reactive protein (hs-CRP) levels before and after treatment (P > 0.05); however, hs-CRP levels improved significantly after treatment compared to baseline (P < 0.05). There was no significant difference in TCM symptom scores between the two groups at baseline. After treatment, both groups showed improvement in symptoms such as diarrhea, poor appetite, vomiting, and abdominal pain (P < 0.05), with the observation group demonstrating significantly better results than the control group (P < 0.05). The overall effective rate in the observation group (93.2%) was higher than that in the control group (89.2%), indicating a statistically significant difference in clinical efficacy (P < 0.05). No significant difference in fecal form-to-stick ratio was found between the two groups at baseline. After treatment, both groups showed improvement in this ratio (P < 0.05), but the observation group demonstrated a more marked improvement—post-treatment form-to-stick ratio was 0.227 ± 0.084, significantly lower than pre-treatment values of 0.495 ± 0.244 (P < 0.05)—indicating that the intervention regimen in the observation group effectively alleviated clinical symptoms and improved relevant indicators. Conclusion: The combination of Shenqu Xiaoshi Oral Liquid and Saccharomyces boulardii powder significantly improves clinical symptoms in children with rotavirus gastroenteritis and helps regulate intestinal microbiota imbalance.
Keywords: Rotavirus gastroenteritis; Diarrhea; Shenqu Xiaoshi Oral Liquid; Saccharomyces boulardii powder; Efficacy
--
